GlobeNewswire by notified

Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting


Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting

London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces the publication of two online abstracts at the annual American Society of Clinical Oncology, to be held from 31 May to 4 June 2024 in McCormick Place Convention Centre in Chicago, Illinois, US.

Abstract Publications:

1.   Title: Immuno-Modulatory Alpha Neutrophils: The first-in-class neutrophil progenitor-based allogeneic immuno-cell therapy with cytotoxic and immunomodulatory functionality for the treatment of solid tumours

Authors: Aoife McGinley, Samuel Florence, Martin James Woodward, Durva Patel, Andrew Willis, Alex Blyth, Alfonso Quintas-Cardama, Oxana Polyakova; LIfT Biosciences Ltd., London, United Kingdom; LIfT Biosciences, London, United Kingdom; Foghorn Therapeutics, Cambridge, MA
Abstract number: e14523
Session type: Publication only
Session title: Developmental Therapeutics—Immunotherapy

2.   Title: Example of a simple and scalable manufacturing process for Immuno-Modulatory Alpha Neutrophils, a specifically designed immuno-cell therapy with direct and indirect anti-cancer activity for solid tumour indications

Authors: Durva Patel, Samuel Florence, Aoife McGinley, Jakub Lich, Urvi Thacker, Alex Blyth, Andrew Willis, Alfonso Quintas-Cardama, Oxana Polyakova; LIfT Biosciences Ltd., London, United Kingdom; LIfT Biosciences, London, United Kingdom; Foghorn Therapeutics, Cambridge, MA
Abstract number: e14512
Session type: Publication only
Session title: Developmental Therapeutics—Immunotherapy

Full versions of the abstracts are available at:

Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented:“We are pleased to have two of our abstracts accepted for online publication at this year's ASCO Annual Meeting, a premier meeting bringing together leaders in the oncology field. Our abstracts show how our manufacturing process not only enhances the efficiency and scalability of our treatments, but also ensures production of the highest quality of therapeutic cells. Our findings demonstrate the successful multimodal mechanisms of action of our IMANs and their capability to immunomodulate the solid tumour microenvironment for long-lasting tumour control, bringing us one step closer to a treatment for solid tumours and sustained clinical benefit for patients. This acceptance signifies the strides our team continue to make in advancing our IMANs towards the clinic and we are glad to share this with the scientific community.”


About LIfT BioSciences

LIfT BioSciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs).

LIfT is working towards expanding LIfT's immunomodulatory therapy approach into other therapeutical areas such immunology and inflammation, and antimicrobial resistance. LIfT is committed to delivering complete remission in high unmet need solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. See

Further information

Investors & Media:
Alex Blyth

ICR Consilium
Mary-Jane Elliott, Namrata Taak, Lindsey Neville
+44 (0)7718

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye